EspeRare Foundation
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Private
- Established
- 2013-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.esperare.org
Clinical Trials
5
Active:3
Completed:1
Trial Phases
2 Phases
Phase 1:4
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 1
4 (80.0%)Phase 2
1 (20.0%)Intraamniotic Administrations of ER004 to Male Subjects With X-linked Hypohidrotic Ectodermal Dysplasia
Phase 2
Recruiting
- Conditions
- X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED)
- Interventions
- First Posted Date
- 2021-07-28
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- EspeRare Foundation
- Target Recruit Count
- 20
- Registration Number
- NCT04980638
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Washington University, St. Louis, Missouri, United States
🇫🇷Hôpital Necker - Enfants Malades, Paris Cedex 15, Paris, France
Rimeporide in Patients With Duchenne Muscular Dystrophy
- First Posted Date
- 2016-03-17
- Last Posted Date
- 2019-07-18
- Lead Sponsor
- EspeRare Foundation
- Target Recruit Count
- 20
- Registration Number
- NCT02710591
- Locations
- 🇫🇷
I-Motion - Hôpital Armand Trousseau, Paris, Ile De France, France
🇮🇹San Raffaele Hospital, Milano, Italy
🇪🇸Santa Creu i Sant Pau Hospital, Barcelona, Spain
News
No news found